Faites connaître cette offre !
Reference : UMR9002-JERDEJ-003
Workplace : MONTPELLIER
Date of publication : Friday, July 31, 2020
Type of Contract : FTC Scientist
Contract Period : 24 months
Expected date of employment : 1 October 2020
Proportion of work : Full time
Remuneration : 29000 /36000 euros per annum depending on experience
Desired level of education : PhD
Experience required : 1 to 4 years
The Dejardin lab is seeking an outstanding postdoctoral candidate to explore a novel mechanism of transposon silencing in mammalian somatic cells at the interface of fundamental epigenetics and immunity in the context of our ERC research project.
Transposable elements represent a large fraction of mammalian genomes and their activity must be tightly restricted to maintain genome stability and cellular identity. Our lab is particularly interested the the chromatin control of retrotransposons in somatic cells. Several mechanisms, involving DNA methylation, histone methylation or small RNA targeting have extensively been described. Our recent chromatin proteomics efforts identified a number of novel pathways, including innate immune sensors on such transposons (Gauchier et al, in prep). The goal of this project is to understand the mechanistic details of these unexpected associations, with far reaching implications in the fields of epigenetics and immunity and inflammation.
The successful candidate will explore this mechanism by using cutting-edge genomics, develop mouse knock-out cell lines and possibly animals, and chromatin biochemistry.
PhD in relation with chromatin and epigenetics
Solid experience in RNA/RNP biochemistry (enzymolgy, binding, etc...)
Modern genomics approaches know-how (RNA-seq, ChiP-seq, etc..)
At least one reference letter from the PhD advisor.
Able to write and communicate in english
Our research group is located in the Institute of Human Genetics which provides a scientifically rich environment and opportunities for young scientists to thrive. IGH is equipped or has an easy access to cutting-edge sequencing/proteomics and imaging facilities.
Constraints and risks
We talk about it on Twitter!